This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (23)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Diabetic Retinopathy  • Macular Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with great interest the recent article by Jonas et al¹ in the January 2003 issue of the ARCHIVES. Because of the authors' statement that eyes can tolerate intravitreal triamcinolone acetonide doses of 25 mg, we decided to evaluate, through the National Institutes of Health, Bethesda, Md, hospital pharmacy, the authors' published techniques^2-3 to reduce the solvent agent, primarily benzyl alcohol, from a commercially prepared triamcinolone acetonide suspension (Volon A 40, 40 mg/mL; Bristol-Myers Squibb, Munich, Germany). We used a triamcinolone acetonide suspension commercially available in the United States (Kenalog-40, 40 mg/mL; Bristol-Myers Squibb, Princeton, NJ), which, according to the manufacturer (T. Douglas, Bristol-Myers Squibb, Munich, oral communication, August 8, 2003), is identical to Volon A 40. Triamcinolone and benzyl alcohol quantification was performed using high-performance liquid chromatography (HPLC) methods.⁴ Different syringe-driven filter units were evaluated including a Millipore filter (Millex-SV 5-µm pore size; Millipore Co, Billerica, Mass) available . . . [Full Text of this Article]

Hanna Rodriguez-Coleman, MD; Peng Yuan, PhD; Hyuncheol Kim, MS; Luisa Gravlin, BS; Sunil Srivastava, MD; Karl G. Csaky, MD, PhD; Michael R. Robinson, MD

Correspondence: Dr Rodriguez-Coleman, National Eye Institute, National Institutes of Health, Department of Health and Human Services, Bldg 10, Room 218B, 10 Center Dr, MSC 1863, Bethesda, MD 20892-1863 (colemanh@nei.nih.gov).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Intravitreal Injection of Triamcinolone for Diffuse Macular Edema—Reply
Jost B. Jonas, Robert F. Degenring, and Ingrid Kreissig
Arch Ophthalmol. 2004;122(7):1086-1088.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Should corticosteroids be considered as part of the standard care with photodynamic therapy?
Zarbin
Arch Ophthalmol 2006;124:563-571.
FULL TEXT